CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Pulmonx Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Pulmonx Corp
700 Chesapeake Dr
Phone: (650) 934-2600p:650 934-2600 REDWOOD CITY, CA  94063  United States Ticker: LUNGLUNG
Business Summary
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. The StratX Platform is a cloud-based quantitative CT analysis service that offers physicians with a report that is designed for its solution, which includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
3845 Electromedical and electrotherapeutic apparatus
3841 Surgical and medical instruments and apparatus
7372 Prepackaged software

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of Board Dana G.Mead 63 10/1/2019 2/1/2010
President, Chief Executive Officer, Director Steven S.Williamson 51 3/15/2024 3/15/2024
Chief Financial Officer and Principal Financial and Chief Accounting Officer MehulJoshi 4/3/2024 4/3/2024
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Aeris Therapeutics, Inc. 10K Gill Street Woburn MA United States

Business Names
Business Name
Aeris Therapeutics
LUNG
Pulmonx Australia Pty Ltd
8 additional Business Names available in full report.

General Information
Number of Employees: 279 (As of 12/31/2023)
Outstanding Shares: 38,811,830 (As of 3/20/2024)
Shareholders: 136
Stock Exchange: NASD
Federal Tax Id: 770424412
Fax Number: (302) 655-5049
Email Address: info@pulmonx.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024